Orexo

Uppsala, Sweden – October 14, 2025 – As previously communicated Orexo will announce the Interim Report for the third quarter of 2025 on October 23 at 8 am CEST.

At 2 pm the same day, analysts, investors and media are invited to a presentation where CEO Nikolaj Sørensen and CFO Fredrik Järrsten will present the latest developments. The company’s Chief Medical Officer, Edward Kim, will also participate to provide an update on the partnership with BARDA and the acceleration of the OX390 project. A Q&A session will follow the presentation.

The presentation will be broadcasted live and participants may access the event via live audiocast and teleconference through the following link: https://investorcaller.com/events/orexo/orexo-q3-report-2025

Registration is required to participate. Once you have registered, you will receive the information needed to join the conference call. Participants will be provided with a dial-in number, a conference ID and a personal user ID – all of which are required to access the call. Please note that questions can be asked via the conference call or submitted through the audiocast.

Prior to the event the presentation material will be available on the website under Investors/Report Archive

For further information contact:
Lena Wange, IR & Communications Director
+46 18 780 88 00
ir@orexo.com
 
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.
 
For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.